Blog posts of '2020' 'October'

Brexpiprazole is a novel D2 dopamine and serotonin 1A partial agonist, called serotonin-dopamine activity modulator (SDAM), and a potent antagonist of serotonin 2A receptors, noradrenergic alpha 1B and 2C receptors. Brexpiprazole is an atypical antipsychotic used in the treatment of schizophrenia and major depressivedisorders. In January 2018, it was approved .

Bosutinib is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Bosutinib is a Bcr-Abl kinase inhibitor for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Bosutinib was approved on September 4, 2012.

Ampicillin is a broad-spectrum, semi-synthetic, beta-lactam penicillin antibiotic with bactericidalactivity. Ampicillin is an antibiotic used to prevent and treat a number of bacterialinfections, such as infections, urinary, meningitis, salmonellosis, and endocarditis. Ampicillin was discovered in 1958 and came into commercial use in 1961.

Almotriptan is a sulfonamide triptan with extracerebral, intracranial vasoconstrictor activity. Almotriptan is a triptan drug for the treatment of migraineheadaches. It was patented in 1992 and approved for medical use in 2000.

Amoxicillin belongs to the class of organiccompounds known as penicillins. Amoxicillin is an antibiotic used to treat a number of bacterialinfections. These include middle earinfection, strepthroat, pneumonia, skininfections, and urinarytractinfections among others. Amoxicillin was discovered in 1958 and came into medical use in 1972. Amoxicillin is available from 2017.

Aprepitant an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents. Aprepitant is used with other medications to help prevent nausea and vomiting caused by cancer drug treatment (chemotherapy). It was approved by the Food and Drug Administration (FDA) in 2003. In 2008, fosaprepitant, an intravenous form of Aprepitant was approved.

Apalutamide is a small molecule and androgen receptor (AR) antagonist with potential antineoplastic activity. It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Neoplasms, Castration-Resistant, among others. Apalutamide was first described in 2007, and was approved for the treatment of prostate cancer in February 2018.